Vaccines against lyme disease: What happened and what lessons can we learn?

Gregory A. Poland

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

This article reviews events that led to the withdrawal of the only vaccine to prevent Lyme disease licensed in the United States. The primary issues that led to the vaccine's withdrawal appear to be a combination of vaccine safety concerns, sparked by a molecular mimicry hypothesis that suggested that the vaccine antigen, outer surface protein A, serves as an autoantigen and hence was arthritogenic; concerns raised by anti-vaccine groups regarding vaccine safety; vaccine cost; a difficult vaccination schedule and the potential need for boosters; class action lawsuits; uncertainty regarding risk of disease; and low public demand. This article reviews lessons learned from these events and proposes that future candidate Lyme disease vaccines are unlikely to be developed, tested, and used within the United States in the near future, thus leaving at-risk populations unprotected.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume52
Issue numberSUPPL. 3
DOIs
StatePublished - Feb 1 2011

Fingerprint

Lyme Disease Vaccines
Vaccines
Molecular Mimicry
Combined Vaccines
Safety
Lyme Disease
Autoantigens
Uncertainty
Appointments and Schedules
Vaccination
Antigens
Costs and Cost Analysis

ASJC Scopus subject areas

  • Infectious Diseases
  • Microbiology (medical)

Cite this

Vaccines against lyme disease : What happened and what lessons can we learn? / Poland, Gregory A.

In: Clinical Infectious Diseases, Vol. 52, No. SUPPL. 3, 01.02.2011.

Research output: Contribution to journalArticle

@article{ee7697b9d247422fbf6c5fb395fb1d0a,
title = "Vaccines against lyme disease: What happened and what lessons can we learn?",
abstract = "This article reviews events that led to the withdrawal of the only vaccine to prevent Lyme disease licensed in the United States. The primary issues that led to the vaccine's withdrawal appear to be a combination of vaccine safety concerns, sparked by a molecular mimicry hypothesis that suggested that the vaccine antigen, outer surface protein A, serves as an autoantigen and hence was arthritogenic; concerns raised by anti-vaccine groups regarding vaccine safety; vaccine cost; a difficult vaccination schedule and the potential need for boosters; class action lawsuits; uncertainty regarding risk of disease; and low public demand. This article reviews lessons learned from these events and proposes that future candidate Lyme disease vaccines are unlikely to be developed, tested, and used within the United States in the near future, thus leaving at-risk populations unprotected.",
author = "Poland, {Gregory A.}",
year = "2011",
month = "2",
day = "1",
doi = "10.1093/cid/ciq116",
language = "English (US)",
volume = "52",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Vaccines against lyme disease

T2 - What happened and what lessons can we learn?

AU - Poland, Gregory A.

PY - 2011/2/1

Y1 - 2011/2/1

N2 - This article reviews events that led to the withdrawal of the only vaccine to prevent Lyme disease licensed in the United States. The primary issues that led to the vaccine's withdrawal appear to be a combination of vaccine safety concerns, sparked by a molecular mimicry hypothesis that suggested that the vaccine antigen, outer surface protein A, serves as an autoantigen and hence was arthritogenic; concerns raised by anti-vaccine groups regarding vaccine safety; vaccine cost; a difficult vaccination schedule and the potential need for boosters; class action lawsuits; uncertainty regarding risk of disease; and low public demand. This article reviews lessons learned from these events and proposes that future candidate Lyme disease vaccines are unlikely to be developed, tested, and used within the United States in the near future, thus leaving at-risk populations unprotected.

AB - This article reviews events that led to the withdrawal of the only vaccine to prevent Lyme disease licensed in the United States. The primary issues that led to the vaccine's withdrawal appear to be a combination of vaccine safety concerns, sparked by a molecular mimicry hypothesis that suggested that the vaccine antigen, outer surface protein A, serves as an autoantigen and hence was arthritogenic; concerns raised by anti-vaccine groups regarding vaccine safety; vaccine cost; a difficult vaccination schedule and the potential need for boosters; class action lawsuits; uncertainty regarding risk of disease; and low public demand. This article reviews lessons learned from these events and proposes that future candidate Lyme disease vaccines are unlikely to be developed, tested, and used within the United States in the near future, thus leaving at-risk populations unprotected.

UR - http://www.scopus.com/inward/record.url?scp=79952569307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952569307&partnerID=8YFLogxK

U2 - 10.1093/cid/ciq116

DO - 10.1093/cid/ciq116

M3 - Article

C2 - 21217172

AN - SCOPUS:79952569307

VL - 52

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 3

ER -